ArticleJournal of diabetes investigation2026
Efficacy and safety of SGLT2 inhibitor on insulin resistance and hyperglycemia in Werner syndrome-A case report.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 48-year-old man was referred to our hospital due to hyperglycemia. His casual plasma glucose and glycated hemoglobin A1c were 25.2 mmol/L and 8.7%, respectively. He had undergone bilateral cataract surgery in his 30s. He exhibited a bird-like face contour, gray hair, alopecia, and bilateral calcifications of the Achilles' tendons, suggestive of Werner syndrome (WS). Genetic analysis revealed compound heterozygous mutations in the WRN gene (mutation c. 3139-1G>C, mutation c. 1105C>T), leading to the diagnosis of WS. Adequate glycemic control was not achieved by the treatment with pioglitazone and metformin. Additional administration of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorated insulin resistance and resulted in an improvement in glycemic control without adverse events. Dapagliflozin may potentially be a choice in treating diabetes associated with WS with an amelioration of insulin resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.